Intratumoral variability of HER2 genetic heterogeneity in breast carcinoma
| Percentage of carcinoma cells with HER2/CEP17 ratio >2.2 | ||||||
| Case | Tumour type | HER2 score | Average | Area 1 | Area 2 | Area 3 |
| H2 | Ductal | 1+ | 10% | 15% | 10% | 5% |
| H6 | Ductal | 3+ | 8% | 10% | 5% | 10% |
| H10 | Ductal | 0 | 12% | 20% | 5% | 10% |
| H39 | Ductal | 0 | 8% | 5% | 10% | 10% |
| H45 | Ductal | 1+ | 15% | 15% | 25% | 5% |
| H50 | Lobular | 3+ | 7% | 15% | 0% | 5% |
| H61 | Ductal | 1+ | 5% | 0% | 0% | 15% |
| H73 | Ductal | 2+ | 45% | 35% | 55% | 45% |
| H76 | Ductal | 3+ | 47% | 45% | 40% | 55% |
| H85 | Ductal | 1+ | 5% | 5% | 5% | 5% |
| H89 | Ductal | 3+ | 15% | 20% | 10% | 15% |
| H92 | Ductal | 0 | 5% | 5% | 5% | 5% |
| H97 | Lobular | 2+ | 17% | 10% | 20% | 20% |
| H98 | Ductal | 2+ | 10% | 15% | 5% | 10% |
| H112 | Ductal | 0 | 18% | 25% | 20% | 10% |
| H113 | Ductal | 1+ | 13% | 10% | 10% | 20% |
| H119 | Ductal | 0 | 25% | 15% | 40% | 20% |
| H136 | Ductal | 2+ | 42% | 30% | 35% | 60% |
| H142 | Ductal | 2+ | 43% | 40% | 55% | 35% |
| H143 | Lobular | 0 | 5% | 0% | 15% | 0% |
| H145 | Ductal | 2+ | 40% | 50% | 30% | 40% |
| H151 | Ductal | 1+ | 5% | 15% | 0% | 0% |
| H153 | Ductal | 2+ | 27% | 30% | 30% | 20% |
| H164 | Ductal | 1+ | 8% | 5% | 10% | 10% |
| H176 | Tubular | 0 | 23% | 25% | 35% | 10% |
| H187 | Ductal | 0 | 7% | 10% | 5% | 5% |
| H188 | Lobular | 2+ | 18% | 10% | 40% | 5% |
| H197 | Ductal | 0 | 20% | 15% | 30% | 15% |
| H200 | Ductal | 0 | 32% | 50% | 30% | 15% |
| H201 | Ductal | 1+ | 13% | 20% | 10% | 10% |
| H209 | Ductal | 2+ | 12% | 10% | 15% | 10% |
| H217 | Ductal | 0 | 5% | 5% | 5% | 5% |
In 32 carcinomas with HER2 genetic heterogeneity, the percentages of carcinoma cells with a HER2/17 centromeric probe (CEP17) ratio greater than 2.2 were determined in three randomly selected areas of invasive breast carcinoma using resection specimens.